# Respiratory Pathogens Data Oct 26 2018 - Feb 2 2019

| Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV / Rhino	Meta pneumo	Adeno	All Corona	Bocca	Myco plasma	Chla mydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
Feb1	0	7	38	1	80	13	53	22	12	58	4	3	1	292	46	751	6.1	n/a	n/a	19.6
Jan 26	0	2	31	2	76	11	57	17	6	62	5	1	1	271	35	947	3.7	19.2	12.6	18.3
Jan 18	0	3	30	0	95	13	63	13	9	64	7	5	0	302	33	1064	3.1	15.7	13.3	1
Jan 11	0	2	20	0	117	12	70	17	10	45	4	6	1	304	22	1026	2.1	12.7	11.6	1
DEC 28	0	4	22	1	128	19	87	21	14	41	4	5	0	346	27	812	3.3	12.7	11.8	9.6
DEC 28	0	5	11	3	105	18	92	15	12	35	11	3	1	311	19	783	2.4	13.7	9.0	3.7
DEC 21	0	2	13	0	105	19	72	10	8	21	10	1	0	261	15	766	2.0	15.6	6.9	7.2
DEC 14	0	0	4	0	55	22	54	3	8	6	6	2	0	160	4	891	0.4	11.0	4.1	5.1
DEC 7	0	0	2	0	63	26	58	9	10	8	2	3	2	183	2	785	0.3	3.6	1.8	3.6
Nov 30	0	0	1	0	42	25	71	9	8	9	5	4	1	175	1	641	0.6	4.2	1.9	1.9
NOV 23	0	2	2	0	51	29	83	5	10	4	3	4	0	193	4	566	0.7	2.4	1.6	2.7
NOV 16	1	0	0	0	25	29	92	3	5	1	4	4	0	164	1	457	0.2	1.7	1.5	0.7
NOV 9	0	0	1	0	23	28	78	4	7	5	1	6	2	155	1	458	0.2	1.2	0.9	1.5
OCT 26	0	0	2	0	18	23	93	1	8	2	3	6	1	157	2	506	0.4	0.9	0.7	1.6

Flu PCR % Rate

ACL RESP. PANEL - POSITIVITY RATE All viruses - 38.8 %

Legend:
- All Corona
- Chla mydia
- Myco plasma
- All Para
- Adeno
- Meta pneumo
- EV / Rhino
- RSV
- Inf B
- InfA-H3
- 2009 H1N1
- InfA-H1
- Bocca

ACL RESP. PANEL - RSV PCR - 10.7%, RSV EIA - 6.6%

ACL RESP. PANEL - Flu PCR - 6.1%, Flu EIA - 19.6%

Correlation between RPPNL (FLU PCR) and Sofia (FLUAG) - Accuracy 96.3%

In the last two months 1589 samples were tested by both methods most of them negative, 47/90 samples were positive by EIA when confirmed by PCR. 47 negative EIA samples were tested positive by PCR method. *(ACL correlation data is compiled on samples collected within <48 h)*

			RPPNL		
			+	**-**	Total
FluAG		**+**	**43**	**11**	54
		-	**47**	**1488**	1535
				Total	**1589**

Dec 1 2018 to Feb 2 2019
FLUAG (Sofia) vs RPPNL (PCR) correlation

%	
47.8	**Clinical Sensitivity**
99.3	**Clinical Specificity**
79.6	**Positive Predictive Value (PPV)**
96.9	**Negative Predictive Value (NPV)**
96.3	**Accuracy**

Jan 26, 2019 **Positivity rate 19.2% -** **Flu A – 98% , Flu B – 2%**

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2018-2019 Season

2018-19 Influenza Season Week 4 ending Jan 26, 2019

ILI Activity Level

- High
- Moderate
- Low
- Minimal
- Insufficient Data

*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.
*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.
*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.
*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.
*For the data download you can use Activity Level for the number and Activity Level Label for the text description.

# A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*

Week Ending Jan 26, 2019 - Week 4

Influenza Activity Estimates

- No Activity
- Sporadic
- Local Activity
- Regional
- Widespread
- No Report

District of Columbia

Guam

Alaska

Hawaii

US Virgin Islands

Puerto Rico

*This map indicates geographic spread and does not measure the severity of influenza activity.

The most prevalent target **were VZV and Crypto – total pos. rate 6.4%**

ACL RMEPNL - CSF POSITIVE TARGETS

Legend: Crypto, VZV, PEV, HHV6, HSV2, HSV1, EV, CMV, S. pneu, S. agal, N. men, L. mono, H. infl, E. coli

The most prevalent bacterial targets was **Campy, Salmonella and Giardia**

ACL GPP - STOOL POSITIVE BACTERIA TARGETS

Legend:
- ■ E. histo
- □ GIARDIA
- ■ CRYP
- ■ CAMPY
- ■ ETEC LT/ST
- □ VIBRIO
- □ E COLI 0157
- ■ SHIGA tox 2
- ■ SHIGA tox 1
- □ SALM
- ■ SHIG

X-axis: FEB, 2018; MAR, 2018; APRIL,...; MAY, 2018; JUNE,...; JULY,...; AUG, 2018; SEPT,...; OCT, 2018; NOV, 2018; DEC, 2018; JAN, 2019

The most prevalent virus target was **Norovirus** type **I / II – 13%** pos. rate

	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	21.3	12.5	1.9	0.3	2.8	0.1	6.8	17.1	62.8

SWAB ONE - POSITIVE TARGETS - Jan 2019

Neuraminidase Inhibitors **Resistance** in samples collected – as of Jan 26, 2019

Per CDC website	Oseltamivir		Peramivir		Zanamivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	431	0.5	431	0.5	431	0
Influenza A (H3N2)	219	0	219	0	219	0
Influenza B	79	0	79	0	79	0

There 0.5 resistance detected.